Pacira Pharmaceuticals PT Raised to $59.00 at Wedbush (PCRX)
Stock analysts at Wedbush hoisted their target price on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $43.00 to $59.00 in a report issued on Thursday, AnalystRatingsNetwork reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 12.08% from the stock’s previous close.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 0.44% on Thursday, hitting $52.64. The stock had a trading volume of 684,285 shares. Pacira Pharmaceuticals has a 1-year low of $15.07 and a 1-year high of $53.75. The stock’s 50-day moving average is $39.89 and its 200-day moving average is $32.66. The company’s market cap is $1.754 billion.
A number of other analysts have also recently weighed in on PCRX. Analysts at Brean Capital raised their price target on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $44.00 to $59.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group raised their EPS on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note to investors on Tuesday. They now have a “buy” rating and a $58.00 price target on the stock. They previously had a $44.00 price target on the stock. Finally, analysts at Barclays Capital raised their price target on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $40.00 to $43.00 in a research note to investors on Friday, September 20th. They now have an “overweight” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $51.40.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.